Is LeMaitre Vascular, Inc. overvalued or undervalued?

As of 23 July 2025, the valuation grade for LeMaitre Vascular, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 45, a Price to Book Value of 5.84, and an EV to EBITDA of 30.21, which suggest that while the company is performing well, it may not be significantly undervalued.
In comparison to its peers, LeMaitre Vascular's P/E ratio of 49.77 is relatively close to TransMedics Group, Inc. at 50.23, while Veracyte, Inc. is considered expensive with a P/E of 50.97. This places LeMaitre in a competitive position within the industry, although it does not stand out as a bargain. Notably, the company's stock has underperformed against the S&P 500 over the past year, returning 5.14% compared to the index's 17.14%, which may reinforce the notion that it is fairly valued rather than undervalued.